NCT02680288View on ClinicalTrials.gov

Lorcaserin Intra Venous Cocaine Effects

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

September 30, 2018

Study Completion Date

November 30, 2019

Conditions
Cocaine Use Disorders
Interventions
DRUG

Lorcaserin, 10 mg

Oral type 2C serotonergic agonist, low-dose

DRUG

Lorcaserin, 20 mg

Oral type 2C serotonergic agonist, high-dose

OTHER

Oral Placebo

Oral inert treatment

Trial Locations (1)

64128

RECRUITING

Kansas City VA Medical Center, Kansas City

Sponsors
All Listed Sponsors
lead

Midwest Biomedical Research Foundation

OTHER

NCT02680288 - Lorcaserin Intra Venous Cocaine Effects | Biotech Hunter | Biotech Hunter